Modified citrus pectin as Anti-Galectin-3 therapy In heart Failure Trial (MAGnIFicenT): a pilot randomised study of the effects of modified citrus pectin on biomarkers of collagen turnover and left ventricular function in optimally medicated patients with heart failure

Hull and East Yorkshire Hospitals NHS Trust (UK)0 个研究点目标入组 100 人开始时间: 2012年7月9日最近更新: 2019年5月5日

适应症

试验速览

暂无简介。

•1. Patients diagnosed with heart failure, who had been or are currently on diuretics, substantiated by a raised NT-pro BNP and /or evidence of left ventricular systolic or diastolic dysfunction
•2. Plasma galectin-3 level > 17.8 ng/mL
•3. Therapy with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and beta-blocker (BB) (unless documented intolerance) for at least 3 months duration.
•4. Aged over 18
•5. If female, not of childbearing age or, if of childbearing age and sexually active, willing to use birth control.

•1. Current decompensated heart failure
•2. Inability to provide informed consent
•3. Use of eplerenone or spironolactone within 30 days of randomization or for more than 7 days within the previous 6 months (because they suppress galectin-3 effects and have potassium sparing effects which could increase the risk of hyperkalemia)
•4. Pregnant or breast-feeding women

发起方

Hull and East Yorkshire Hospitals NHS Trust (UK)